Stuart Ingis on the benefits of showing the public how advertisers and marketers use data and creating a global regulatory framework.
New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
This includes Sarepta Therapeutics' Exondys 5 and Vertex Pharmaceuticals' Orkambi.
Drugs approved through the accelerated approval pathway, as well as psychiatric drugs, were more likely to have a safety issue following FDA approval.
The market for health data and technology is growing, but the industry must also address concerns about privacy, standards, and diversity.
HHS Secretary Tom Price calls for health IT that works for clinicians and better interoperability.
This is likely due, in part, to the increasingly complex nature of new specialty drugs.
An analysis of claims data found that an off-label settlement for one Eli Lilly drug did not significantly change how often it was prescribed off-label after the settlements.
These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.
Organizations are focusing on better ways to verify HCPs' digital identities.
Docs said patients asked about drugs from DTC ads six times in a typical week, compared to just twice a week five years ago.
How the retail pharmacy chain uses customer data to make its marketing messages relevant.
There are dozens of players, including leaders like IBM Watson Health and Verily as well as smaller concerns, lining up to sell pharma access to some sort of data solution.
The first step is to seek leadership support, she says.
Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.